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Abstract
Mutations in the MTM1 gene, encoding the phosphoinositide phosphatase myotubularin, are responsible for the
X-linked centronuclear myopathy (XLCNM) or X-linked myotubular myopathy (XLMTM). The MTM1 gene was first
identified in 1996 and its function as a PtdIns3P and PtdIns(,5)P2 phosphatase was discovered in 2000. In recent
years, very important progress has been made to set up good models to study MTM1 and the XLCNM disease such
as knockout or knockin mice, the Labrador Retriever dog, the zebrafish and the yeast Saccharomyces cerevisiae.
These helped to better understand the cellular function of MTM1 and of its four conserved domains: PH-GRAM
(Pleckstrin Homology-Glucosyltransferase, Rab-like GTPase Activator and Myotubularin), RID (Rac1-Induced
recruitment Domain), PTP/DSP (Protein Tyrosine Phosphatase/Dual-Specificity Phosphatase) and SID (SET-protein
Interaction Domain). This review presents the cellular function of human myotubularin MTM1 and its yeast homolog
yeast protein Ymr1, and the role of MTM1 in the centronuclear myopathy (CNM) disease.
Keywords: Centronuclear myopathy; Myotubularin; MTM1; Yeast,
Mtm1 KO mice
Introduction
The X-linked centronuclear myopathy (XLCNM) or X-linked
myotubular myopathy (XLMTM) was first described in 1966 by Spiro
and coll. and named myotubular myopathy [1]. A year later, this
disease was also described as a centronuclear myopathy [2]. This
myopathy, affecting 1 in 50000 male births, is caused by mutations in
the MTM1 gene (OMIM® ID 310400) coding for a phosphoinositides
phosphatase [3,4]. The responsible gene was localized on the X-
chromosome Xq28 region in 1990 [5] and first identified by Laporte
and coll. in 1996 [6]. The MTM1 gene is 104 749 bp in length and
consists of 15 exons [7]. MTM1 is ubiquitously expressed since its 3.9
kb transcript was detected in many tissues including hart, brain,
placenta, liver, muscles and pancreas [6,7]. However, the disease
specifically affects skeletal muscles but no muscle specific exon or
splicing variant has been detected to explain this selectivity [6].
MTM1 mutations are subjected to an X-linked recessive mode of
inheritance. Indeed, the mother, usually asymptomatic, is the
heterozygous carrier of the MTM1 mutations [8]. To date, more than
200 different mutations have been identified in the MTM1 gene
[8-14]. The majority of mutations are nonsense or frameshift
mutations leading to the absence of MTM1 or to the production of a
truncated non-functional protein. Missense mutations have also been
described and are responsible for mild to severe forms of myopathy
(Figure 1). Interestingly, these different mutations are distributed
throughout the MTM1 gene and affect the various domains of the
MTM1 protein but lead to the same disease with various degrees of
severity (Figure 1).
Figure 1: Missense mutations identified in MTM1. Schematic representation of protein domains found in the human MTM1 phosphatase.
Each vertical line represents a missense mutation found in XLCNM patients. Colors indicate the severity of the centronuclear myopathy
disease associated to each mutation.
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Clinical and Histological Features of MTM1 Myopathy
XLCNM was first identified in 1966 based on the clinical study of a
12-year-old boy presenting a general muscular weakness,
ophtalmoplegia and ptosis [1]. Muscular biopsies showed
characteristics of immature muscles with hypotrophic fibers and
centrally located nuclei that resembled fetal myotubes, leading the
disease to be named myotubular myopathy. The disease was believed
to result from a defect in muscle maturation. This was later supported
by studies showing that Vimentin and the prenatal myosin heavy
chain (MHC) isoform, two proteins specific of fetal myotubes, were
detected in muscles of XLCNM patients [15,16]. However, the study of
Mtm1 knockout (KO) mice revealed that these phenotypes result from
an inability to maintain muscles in their mature state. The Mtm1 KO
mice show clinical signs of the myopathy starting around 4 weeks of
age and most die in the first 2 months from progressive and
generalized muscle disorders having the signs of XLCNM [17]. The
etiology of the disease has been validated by other studies, despite the
fact that markers of immature muscle are not always present in
XLCNM patients [18].
XLCNM is characterized by generalized muscle weakness and
respiratory distress in affected males whereas female heterozygous
carriers are generally asymptomatic. The disease ranges from severe to
mild with some severe forms leading to neonatal death due to
respiratory failure. In healthy mature muscles, nuclei are localized at
the periphery of the fiber close to the plasma membrane, whereas in
XLCNM muscles, many nuclei are centrally localized. The centrally
located nuclei are generally surrounded by a halo lacking contractile
elements but containing mitochondria aggregates and glycogen
granules [19].
The Myotubularin Family of Protein
Myotubularins belong to the PTP/DSP (Protein Tyrosine
Phosphatase/Dual-Specificity Phosphatase) super-family. MTM, the
founding member of the myotubularin family, dephosphorylates the
D3 phosphate of the inositol ring of two types of phosphoinositides
(PIP): the phosphatidylinositol 3-phosphate (PtdIns3P) and the
phosphatidylinositol 3,5-bisphophate (PtdIns(3,5) P2) [3,4,20,21].
Myotubularin homologues are found in all eukaryotic cells, from
Plant to Fungi and Human (Table 1) [22,23]. Most eukaryotes have
several myotubularin isoforms, however in the yeast Saccharomyces
cerevisiae there is only one named Ymr1 (Yeast myotubularin related
1) despite its whole-genome duplication [2,24]. In Human, there are
14 paralogues of myotubularin and one closely related phosphatase
termed Jumpy. The high degree of conservation among members of
the myotubularin family suggests they arose by gene duplication and
perform important cellular functions in different cell types [2,23].
Myotubularins are PIP phosphatases, but among the 14 human
myotubularins some members do not possess the cysteine or the
arginine residue of the CX5R PTP/DSP conserved catalytic motif
rendering these phosphatases catalytically inactive. This allows the
classification of myotubularins in either active phosphatases: MTM,
MTMR1, MTMR2, MTMR3 (FYVE-DSP1), MTMR4 (FYVE-DSP2),
MTMR6, MTMR7 and MTMR8 and, inactive phosphatases: MTMR5
(Sbf1), MTMR13 (Sbf2), MTMR9 (LIP-STYX), MTMR10 (FLJ20313),
MTMR11 (CRA) and MTMR12 (3-PAP) [25]. Besides MTM1
mutations affecting muscle, defects in the active MTMR2 or the
catalytically inactive MTMR13 myotubularins result in a neuropathy,
the Charcot-Marie-Tooth syndrome [26,27].
Organism Number ofparalogues Paralogues
Homo sapiens 14 + 1 MTM1, MTMR1-13,hJumpy
Mus musculus 14 + 1 MTM1, MTMR1-13,mJumpy
Canis lupus 13 MTM1, MTMR1-7,MTMR9-13
Danio rerio 14+1 MTM1, MTMR1-13,dJumpy
Drosophila melanogaster 7
Mtm, MtmR2/3,
MtmR3/4, MtmR6/7/8,
MtmR9, MtmR10/11/12,
MtmR3/13
Caenorhabditis elegans 5 MTM-1, MTM-3, MTM-5,MTM-6, MTM-9
Saccharomyces cerevisiae 1 YMR1
Arabidopsis thaliana 2 AtMTM1, AtMTM2
Table 1: Number of myotubularins found in various organisms.
The Yeast Ymr1 Myotubularin
In yeast S. cerevisiae, deletion of the YMR1 gene coding for the only
myotubularin homologue is not lethal for the cell. Nonetheless, ymr1Δ
knockout cells have fragmented vacuoles (the yeast lysosome) (Figure
2) and a two-fold increase in intracellular levels of PtdIns3P [4,28,29].
The Ymr1 protein shares the regulation of intracellular PtdIns3P
levels with synaptojanin-like phosphatases Sjl2/Inp52 and Sjl3/Inp53.
Indeed, the triple deletion of YMR, SJL2 and SJL3 is lethal. However,
Sjl2 and Sjl3 phosphatases are less specific than Ymr1 since they also
dephosphorylate D4 and D5 positions of the inositol ring, whereas
Ymr1 dephosphorylates only at position D3 [30]. In wild-type yeast
cells, YMR1 overexpression induces a protein trafficking defect from
the Golgi apparatus towards the vacuole along the VPS (vacuolar
protein sorting) pathway [28]. Moreover, the ymr1Δ sjl3Δ double
mutant strain has defects in intracellular trafficking at endosomes [28].
The Ymr1 myotubularin is also required for autophagy since the
phosphatase-dead Ymr1-C397S catalytic mutant is impaired in
autophagy and the Sjl3 synaptojanin cannot substitute Ymr1 for this
function [31]. Electron microscopy analyses under autophagic
conditions show that autophagosomes bearing several Atg proteins
accumulate in the cytoplasm of ymr1Δ mutant cells. In wild-type cells
under these autophagic conditions, Ymr1 localizes to the phagophore
assembly site (PAS) suggesting its phosphatase activity could be
required to regulate the PtdIns3P turnover necessary for
autophagosome maturation [31].
The fragmented vacuolar phenotype and the PtdIns3P turnover
defects observed in yeast ymr1Δ mutant cells are restored by
expressing the human MTM1 myotubularin (Figure 2), showing that
yeast is a model well suited to study MTM1 [29]. Moreover, the
catalytic activity of MTM1 is required to complement the vacuolar
defect of the ymr1Δ mutant cells (Figure 2) [29]. Therefore, yeast can
be used to determine the in vivo phosphatase activity of different
MTM1 patient mutants with an easy assay based on the vacuolar size.
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Figure 2: Human MTM1 complements the fragmented vacuolar
phenotype of the yeast ymr1Δ mutant cells. Yeast wild-type (WT)
or ymr1Δ mutant cells transformed with an expression plasmid
(pVV200) bearing wild-type human MTM1 or the catalytic-dead
MTM1-C375S mutant were grown to exponential phase and the
vacuoles were stained by FM4-64. Cells were observed by
fluorescence microscopy with DIC (Nomarski) and TRITC
(FM4-64) filters. Images were treated with ImageJ software
(Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, 1997–2009).
The Human Myotubularin MTM1
The human MTM1 protein is 603 amino acids in length with 4
domains: PH-GRAM (Pleckstrin Homology-Glucosyltransferase, Rab-
like GTPase Activator and Myotubularin), RID (Rac1-Induced
recruitment Domain), PTP/DSP and SID (SET-protein Interaction
Domain) (Figure 3). All human paralogues and the yeast Ymr1
myotubularins share these 4 domains. Besides these core domains,
MTM1 has also a C-terminal coiled-coil motif followed by a PDZ
binding domain but no transmembrane domain.
The PH-GRAM Domain
The PH-GRAM domain is at the N-terminus of the MTM1 protein
(amino acids 29 to 160). Its name derives from its homology to the PH
(Pleckstrin Homology) and GRAM (Glucosyltransferase, Rab-like
GTPase Activator and Myotubularin) domains (Figure 1). The PH-
GRAM domain is present in almost all eukaryotic myotubularins,
suggesting that its architecture was established early in evolution,
perhaps coinciding with the acquisition of the characteristic PTP/DSP
myotubularin phosphatase domain [23].
The PH domain was initially found in a platelet and leucocyte
protein named Pleckstrin (Platelet and Leucocyte C Kinase Substrate).
The Pleckstrin PH domain comprises between 100 and 120 amino
acids organized in an up-and-down β-barrel of seven antiparallel β-
strands followed by a C-terminal α-helix [32]. It binds membrane
lipids such as phosphoinositides but also recruits effectors and/or
regulatory proteins. Hundreds of proteins with a PH domain have
been identified in human cells and display a great variability, especially
in the loops connecting the β-strands. All PH domains bind
phosphoinositides, but they do not have the same specificity and
affinity for their substrate(s). Indeed, it is estimated that only 10% of
the PH domains bind PIPs with high affinity and specificity [33].
The GRAM domain was identified by Doerks and coll. in a number
of human proteins such as myotubularins [34]. Since this GRAM
domain displays high structural similarities with the PH domain, it
was renamed PH-GRAM domain. Like PH domains, PH-GRAM
domains also bind to both PIPs and effector proteins. The affinity of a
PH-GRAM domain for a given PIP could play a key role in targeting
the various myotubularins to a specific intracellular compartment.
Indeed, PH-GRAM domain amino acids sequence can be very
divergent, suggesting that these domains could have distinct molecular
properties and cellular functions [23]. The PH-GRAM domain of
MTM1 has the highest affinity for the endosomal enriched
phosphoinositide PtdIns(3,5)P2 [35]. Different XLCNM patient
mutations affecting the PH-GRAM domain of MTM1 were tested for
PIP interaction, the V49F shows a significant decrease in PtdIns (3,5)
P2 binding, whereas the R69C, L70P or L87P have only a minor effect
on PtdIns(3,5)P2 binding [35]. Interestingly, the MTM1-V49F mutant,
responsible for a severe form of myopathy, shows a twofold decrease
in phosphatase activity compared to the MTM1-R69C mutant,
associated with milder forms of myopathy, which displays wild-type
phosphatase activity [29]. The crystal structure of MTMR2 (PDB
accession number 1ZSQ) was used to model the MTM1 protein and
the model shows that residue R69 is at the MTM1 protein surface,
whereas residue V49 is more buried in the interior of the protein
(Figure 3). This suggests that mutation of this V49 residue might be
more deleterious for the overall structure of the MTM1 PH-GRAM
domain.
Figure 3: Model of the MTM1 protein with the different domains.
This MTM1 protein model is based on the MTMR2 crystal
structure (PDB accession number 1ZSQ) [29]. The different
domains are shown in different colors: PH-GRAM (orange), RID
(yellow), PTP/DSP (blue), SID (green). The V49 and R69 residues
are highlighted in red. The figure was prepared with the PyMOL
software (The PyMOL Molecular Graphics System, Version 1.5.0.1
Schrödinger, LLC.).
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The RID Domain
The RID domain (amino acids 161-272 of MTM1) was identified
for its ability to localize MTM1 at the plasma membrane in cells
expressing a constitutively activated Rac1 GTPase mutant [36]. Rac1
belongs to the Rho and Cdc42 GTPase subfamily involved in plasma
membrane ruffling and endocytosis through actin cytoskeleton
remodeling [37]. Expression of the dominant active mutant Rac1-V12
induces widespread plasma membrane remodeling and MTM1
localization to these ruffles [36]. Mutations or small deletion into the
RID domain prevent MTM1 localization to these Rac1-V12 induced
membrane ruffles, showing that the RID domain is crucial for its
plasma membrane localization [36]. Moreover, the RID domain of
MTM1 also interacts with Desmin, an intermediary filament protein
involved in shaping muscle cells [38].
The RID domain plays a crucial role in the recruitment of MTM1 to
plasma membrane ruffles after Rac1 GTPase activation but this
membrane localization could also be enhanced in the muscle cells
through its interaction with the actin cytoskeleton via Desmin.
The PTP/DSP Phosphatase Domain
The lipid phosphatase PTP/DSP (amino acids 273-471 of MTM1)
domain is also highly conserved among the different myotubularins.
The catalytic site of the PTP/DSP domain consists of a highly
conserved CX5R motif (VHCSDGWDRT) that defines the active
myotubularin subfamily [25]. It was shown that three residues of this
catalytic site are important: the cysteine and arginine residues to
stabilize the substrates by forming a thiol-phosphate intermediary and
the aspartate involved in the product release.
Initially described as a protein tyrosine phosphatase (PTP) due to
the presence of the CX5R motif characterizing this type of enzyme, it
was later shown that the PTP/DSP domain of MTM1
dephosphorylates PtdIns3P and PtdIns(3,5)P2 in PtdIns and PtdIns5P
respectively [3,4,21]. This particular PIP substrate preference is no
exception, since the human phosphatase PTEN (Phosphatase and
TENsin homologue), also characterized by a CX5R motif, displays a
substrate preference towards PtdIns (3,4,5) P3 [39].
In keeping with the high degree of conservation of the
myotubularin PTP/PSD domain, myotubularins carrying the CX5R
motif are enzymatically active and dephosphorylate PtdIns3P and
PtdIns(3,5)P2 in vitro [21]. In vivo, in yeast cells or in the mouse
muscle, residue C375 of the CX5R motif is also necessary for MTM1
phosphatase activity [29].
The SID Domain
The SID domain (amino acids 435-486 of MTM1) was identified in
1998 by Cui and coll. in the inactive myotubularin Sbf1 (SET-binding
factor)/MTMR5 [40]. Contrary to the other domains found in
myotubularins, this domain is specific to the myotubularin family. It
was shown that the SID domain binds to proteins containing the SET
domain (Suvar3-9, Enhancer of zeste, Tritorax) found in proteins
involved in epigenetic regulation of genes [41].
Recombinant MTM1 and MTMR5/Sbf1 were shown to bind the
yeast methyltransferase Set1 SET domain in vitro and the human
histone methyltransferase SET domain in vivo [40]. Overexpression of
the MTMR5/Sbf1 inhibits the C2 myoblast fusion to form myotubes,
and the SID domain is required for this inhibition [40]. Thus the
interaction between the SID domain of myotubularins and proteins
with a SET domain could play an important role in regulating the
expression of some genes.
Study of XLCNM in Different Animal Model
Different models are used to better understand the XLCNM
pathology, among them the zebrafish, mouse and Labrador Retriever
are the ones mimicking best the different hallmarks of this
centronuclear myopathy. The zebrafish Danio rerio has one MTM1
homologue and 12 of the 14 human MTMR genes homologues (Table
1). The antisens morpholino strategy was used to knockdown the
MTM1 gene and the resulting MTM morphants had severe muscle
pathologies with mislocalized nuclei, myofibers hypotrophy and T-
tubule disorganization [42].
The best studied XLCNM model is the Mtm1 knockout mouse
model generated by Buj-Bello and coll. [17]. This Mtm1 KO mouse
model is viable but its lifespan is severely reduced and it shows all the
XLCNM phenotypes with muscle weakness, muscle fibers hypotrophy
and accumulation of central nuclei [17]. The XLCNM like phenotype
of these Mtm1 KO mice can be corrected by adeno-associated virus
AAV-mediated intramuscular injection of wild-type MTM1 [43].
Interestingly, the centronuclear myopathy phenotypes of these Mtm1
KO mice are also rescued by a catalytic-dead MTM1-C375S mutant or
by an inactive MTM1-S376N mutant found in patients, suggesting that
the lack of catalytic phosphatase activity is not the main cause of the
disease [29]. However, these different gene therapies were based on
muscular injection of AAV-MTM1 and could only determine whether
the histological features of the XLCNM disease were corrected.
Recently a new therapy based on the systemic delivery of the MTM1
cDNA under the control of the muscle-specific desmin promoter was
tested in the Mtm1 KO mice [44]. The distinctive histological features
of the XLCNM disease (centronuclear nuclei, aberrant accumulation
of mitochondria and T-tubules misorganization) are restored and the
gene therapy also prolongs the survival and the muscular strength of
the treated Mtm1 KO mice [44]. These promising results pave the way
to a clinical trial of gene therapy for XLCNM. Another model mouse
was developed called Mtm1 pR69C, which is a knockin of the MTM1-
R69C patient mutation. These Mtm1 pR69C mice display reduced
levels of MTM1-R69C transcripts and facilitate the study of XLCNM
since they present less severe symptoms of the disease [45]. Recently,
Mtm1 KO and Mtm1 pR69C mice were used to test a new therapy
based on intramuscular injection of a muscle-specific monoclonal
antibody fused N-terminally to the MTM1 protein [46]. This strategy
leads also to an improvement of the XLCNM-associated phenotypes,
showing that either gene therapy or exogenous protein
supplementation therapy show promise for treatment of the XLCNM
disease.
The last model for XLCNM is the Labrador Retriever, a very
important model for testing new therapeutic strategies because it is a
large animal model that best mimics the human pathology and that the
centronuclear myopathy cnm mutation results from a spontaneous
genetic abnormality (mutation MTM1-N155K) [47,48]. Recently a
systemic MTM1 AAV-mediated therapy showed that not only
histological features of the XLCNM disease could be rescued by AAV-
MTM1 injection in the Labrador Retriever cnm mutant dogs, but that
this gene therapy also led to prolong survival associated with improved
muscular strength, locomotion and respiratory functions [44].
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Conclusion
To date, more than 200 different mutations linked to centronuclear
myopathy have been identified in the MTM1 gene and these
mutations are present in the different domains of the MTM1 protein
(Figure 1). All these mutations lead to the same disease with only the
severity varying. Moreover, many mutations responsible for XLCNM
affect amino acid residues that are conserved throughout evolution,
suggesting that these residues could be important for the cellular
function of MTM1.
The identification of mutations in the MTM1 gene as the sole cause
of the disease has allowed for the pursuit of gene therapy approaches
to treat the associated centronuclear myopathy disease. To this effect, a
systemic injection of AAV-MTM1 in Mtm1 KO mice was successful
and conferred long-term survival of mice that displayed muscle
robustness and no centronuclear myopathy histological features [44].
Since the XLCNM etiology in mice is somewhat different than in
humans, the authors also used the Labrador Retriever to test this
promising therapy and obtained a similar success as in mice [44].
Whereas therapeutic research has made great progress, progress in
fundamental research on the disease and on myotubularins in general
is much slower. Indeed, the link between this phosphatase activity and
the disease is only poorly understood since mutations are present not
only in the catalytic PTP/DSP domain but also in the other MTM1
domains (Figure 1). Moreover some patient mutations responsible for
severe forms of the disease display wild-type catalytic phosphatase
activity [29]. These results were acquired through the use of yeast S.
cerevisiae as a model because it allows the in vivo analysis of a
myotubularin in the absence of its numerous paralogues (Table 1).
These findings suggested that XLCNM Mtm1 KO mice phenotypes
could be ameliorated by AAV-mediated muscular expression of the
MTM1-C375S phosphatase-dead myotubularin, which was indeed
observed [29]. This unexpected finding raises the question about the
involvement of the PIP phosphatase activity of MTM1 in the disease
and the other functions MTM1 carries out. However, this study has to
be confirmed by a systemic expression of AAV-MTM1-C375S to show
that the lifespan and muscular strength of Mtm1 KO mice are
ameliorated. Since it seems that the phosphatase activity is only
marginally involved in the disease, this suggests that MTM1 is
involved in a different interaction network than are the other
myotubularins. In this regard we know that mutations in the
amphiphysin BIN1 and the dynamin DNM2 also cause centronuclear
myopathies but the link with MTM1 is still unclear [49]. The results
found in recent papers strongly underline the power interplay between
S. cerevisiae, the mouse and the dog models would have on the better
understanding of why mutations in this ubiquitously expressed MTM1
gene are responsible for a muscle specific disease. This is also true for
other questions of interest such as why MTM1 mutations are not
compensated by other closely related active myotubularins such as
MTMR1 or MTMR2 also present in the muscles [25].
It is abundantly clear that studying the more tractable XLCNM will
benefit the study of other myotubularin diseases such as the Charcot-
Marie-Tooth syndrome involving either MTMR2 or MTMR13. And
more broadly, understanding these two very different myotubularins
will help us understand the complex functions and regulations of the
other myotubularins.
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